Get the Stockscreener App
393.10
4.48%
16.84
After Hours:
393.10
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $393.10, with a volume of 3.37M.
It is up +4.48% in the last 24 hours and up +9.70% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$376.26
Open:
$383.25
24h Volume:
3.37M
Relative Volume:
1.29
Market Cap:
$212.16B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
27.34
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
+7.33%
1M Performance:
+9.70%
6M Performance:
+14.87%
1Y Performance:
+30.47%
1-Day Range:
$382.21
$398.00
1-Week Range:
$359.21
$398.00
52-Week Range:
$269.77
$398.00
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
393.10 | 203.07B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,220.66 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
266.73 | 640.91B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
263.20 | 453.91B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
131.82 | 322.95B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
159.85 | 296.72B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen (NASDAQ:AMGN) Sets New 12-Month HighTime to Buy? - MarketBeat
Amgen stock jumps as investors appear to look past Tavneos overhang and toward earnings - Quiver Quantitative
Amgen shares may move 4.6% on Aug. 4 earnings release By Investing.com - Investing.com South Africa
Earnings Preview: Amgen (AMGN) Q2 Earnings Expected to Decline - Yahoo Finance
Amgen (AMGN) Expected to Post Earnings on Tuesday - MarketBeat
Amgen stock hits all-time high at 391.3 USD - Investing.com
Amgen makes case to continue selling drug that FDA claims can be deadly - The Business Journals
Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees - The Motley Fool
Barclays Adjusts Amgen Price Target to $360 From $350, Maintains Equalweight Rating - marketscreener.com
The Manufacturers Life Insurance Company Raises Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Bought by Quantinno Capital Management LP - MarketBeat
Empowered Funds LLC Sells 38,200 Shares of Amgen Inc. $AMGN - MarketBeat
Former AbbVie, Amgen exec Severino takes the reins at Sarepta - FirstWord Pharma
For Himself and His Daughters: One Father’s Journey with Thyroid Eye Disease (TED) - Amgen
Amgen stock trades steadily as investors weigh recent earnings and pipeline milestones - Ad-hoc-news.de
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo! Finance Canada
Amgen price bolsters gainsForecast today27-07-2026 - Economies.com
Amgen Stock Erased a 17% Drawdown. A MariTide Switch Study Explains Why. - TIKR.com
Orbimed Advisors LLC Purchases Shares of 39,900 Amgen Inc. $AMGN - MarketBeat
Price-Driven Insight from (AMGN) for Rule-Based Strategy - Stock Traders Daily
Amgen stock extends focus on earnings and guidance - Ad-hoc-news.de
Amgen stock trades steadily as revenue growth and obesity pipeline shape investor focus - Ad-hoc-news.de
Amgen stock trades steady as oncology and cardiovascular pipeline supports valuation - Ad-hoc-news.de
Amgen (AMGN) Beat Revenue Forecasts, Is The Stock Overvalued? - simplywall.st
Amgen stock steadies after Q2 2026 growth - AD HOC NEWS
Lombard Odier Asset Management Switzerland SA Has $14.53 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Purchased by OMERS ADMINISTRATION Corp - MarketBeat
Amgen Inc. $AMGN Shares Sold by Healthcare of Ontario Pension Plan Trust Fund - MarketBeat
Entropy Technologies LP Buys Shares of 9,161 Amgen Inc. $AMGN - MarketBeat
Gabelli Funds LLC Reduces Stake in Amgen Inc. $AMGN - MarketBeat
Aristotle Atlantic Partners LLC Purchases Shares of 4,000 Amgen Inc. $AMGN - MarketBeat
Amgen stock trades steadily as oncology and cardiovascular pipeline supports long term growth - AD HOC NEWS
Amgen stock trims losses as Repatha data and oncology pipeline support long term growth - AD HOC NEWS
Why MrBeast, Stand Up To Cancer, and Amgen Joined Forces to Support Pediatric Cancer Research - Amgen
Amgen Inc (AMG) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
Amgen stock trades steadily as investors weigh Repatha growth and recent earnings - AD HOC NEWS
Amgen Inc (AMGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aristotle Capital Management LLC Lowers Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen stock edges higher as KRAS lung cancer data and revenue growth support outlook - AD HOC NEWS
Amgen stock trades steadily as recent earnings and obesity drug pipeline shape outlook - AD HOC NEWS
Amgen submits new data to challenge FDA's proposal to withdraw Tavneos - Reuters
Amgen Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Amgen shares new analysis with FDA in bid to keep Tavneos on the market - Endpoints News
Amgen stock trades steady as oncology and cardiovascular drugs support outlook - AD HOC NEWS
Amgen Inc. Revenue Breakdown – HAN:AMG - TradingView
Amgen hands in data package in hopes of FDA hearing for Tavneos defense - Fierce Pharma
Amgen submits new data to challenge FDA’s proposal to withdraw Tavneos - 1470 & 100.3 WMBD
Amgen stock trades steady as recent earnings and pipeline updates shape investor focus - AD HOC NEWS
Amgen Says Strongly Disagrees With FDA'S Proposal To Withdraw Tavneos From The U.S. Market - TradingView
Amgen Inc. $AMGN Shares Sold by Oak Associates Ltd. OH - MarketBeat
Public Employees Retirement System of Ohio Grows Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):